Literature DB >> 17889675

Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.

Kirsten D Mertz1, Francesca Demichelis, Robert Kim, Peter Schraml, Martina Storz, Pierre-André Diener, Holger Moch, Mark A Rubin.   

Abstract

Microvessel density (MVD) has been reported to have prognostic relevance for clear cell renal cell carcinoma (ccRCC). However, this finding is controversial because of the difficulty of MVD evaluation in this complex vascularized tumor type. The present study evaluates the use of an automated quantitative analysis (AQUA) system for objective and reproducible determination of tumor vascularization in clear cell renal cell carcinoma (ccRCC). The AQUA system was applied to tissue microarrays with 284 primary ccRCC tumors. To determine angiogenesis in ccRCC, we created an epithelial/stromal mask consisting of CD10, epithelial membrane antigen, and vimentin to distinguish epithelial tumor cells from CD34-positive endothelial cells. Using immunofluorescence and computer-aided quantification of CD34 expression, we measured the relative microvessel area (MVA) and compared the MVA to the manually counted MVD. The MVA determined by AQUA in a test set with 209 ccRCCs ranged from 0% to 30.3% (mean +/- SD, 10.1% +/- 6.3%). The manually determined MVD ranged from 6 to 987 vessels/mm(2) (416.8 +/- 252.8 vessels/mm(2)). MVA and MVD were significantly correlated (P < .001). A larger MVA was associated with histologic grade (P < .001), tumor stage (P =.008), presence of metastasis (P = .005), presence of sarcomatoid areas (P < .001), and tumor-specific survival (P < .001). Using MVA as defined in the test set, all associations with clinical and pathologic parameters were confirmed in a second independent validation set. MVA determination by AQUA is an objective and reliable method to quantify tumor vascularization in ccRCC. A large MVA correlates with a high MVD and is associated with better patient prognosis.

Entities:  

Mesh:

Year:  2007        PMID: 17889675     DOI: 10.1016/j.humpath.2007.05.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Authors:  Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

2.  Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Authors:  Dorothee Pflueger; Andrea Sboner; Martina Storz; Jasmine Roth; Eva Compérat; Elisabeth Bruder; Mark A Rubin; Peter Schraml; Holger Moch
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

Review 3.  Radiomics in Kidney Cancer: MR Imaging.

Authors:  Alberto Diaz de Leon; Payal Kapur; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2019-02       Impact factor: 2.266

4.  Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.

Authors:  Yue Zhang; Payal Kapur; Qing Yuan; Yin Xi; Ingrid Carvo; Sabina Signoretti; Ivan Dimitrov; Jeffrey A Cadeddu; Vitaly Margulis; Naira Muradyan; James Brugarolas; Ananth J Madhuranthakam; Ivan Pedrosa
Journal:  Clin Genitourin Cancer       Date:  2015-08-29       Impact factor: 2.872

5.  Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Authors:  Lucia B Jilaveanu; Maneka Puligandla; Sarah A Weiss; Xin Victoria Wang; Christopher Zito; Keith T Flaherty; Marta Boeke; Veronique Neumeister; Robert L Camp; Adebowale Adeniran; Michael Pins; Judith Manola; Robert S DiPaola; Naomi B Haas; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2017-10-24       Impact factor: 12.531

6.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.

Authors:  Naomi B Haas; Xinyi Lin; Judith Manola; Michael Pins; Glenn Liu; David McDermott; David Nanus; Elisabeth Heath; George Wilding; Janice Dutcher
Journal:  Med Oncol       Date:  2011-02-06       Impact factor: 3.064

7.  Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity.

Authors:  Qing Yuan; Payal Kapur; Yue Zhang; Yin Xi; Ingrid Carvo; Sabina Signoretti; Ivan E Dimitrov; Jeffrey A Cadeddu; Vitaly Margulis; James Brugarolas; Ananth J Madhuranthakam; Ivan Pedrosa
Journal:  Clin Genitourin Cancer       Date:  2016-04-22       Impact factor: 2.872

8.  Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.

Authors:  Rotem S Lanzman; Phil M Robson; Maryellen R Sun; Amish D Patel; Kimiknu Mentore; Andrew A Wagner; Elizabeth M Genega; Neil M Rofsky; David C Alsop; Ivan Pedrosa
Journal:  Radiology       Date:  2012-10-09       Impact factor: 11.105

9.  Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.

Authors:  Wesam M Osman; Nermeen S Youssef
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model.

Authors:  Greg M Thurber; Jose L Figueiredo; Ralph Weissleder
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.